Form 4: Supernus Pharmaceuticals CEO Jack A. Khattar Reports Stock Transactions
SEC Form 4 Filing
Jack A. Khattar, CEO of Supernus Pharmaceuticals, reports the acquisition and disposal of company stock and performance share units on December 27, 2024.
Summary
- On December 27, 2024, Jack A. Khattar, the President and CEO of Supernus Pharmaceuticals, engaged in transactions involving the company's common stock and performance share units.
- Khattar acquired 38,640 shares of common stock upon the settlement of performance share units granted on February 22, 2024.
- He also acquired 14,000 shares of common stock upon the settlement of performance share units granted on February 23, 2023.
- The company withheld 18,567 shares to satisfy tax obligations related to the vesting of performance share units at a price of $35.59.
- An additional 6,666 shares were withheld for tax purposes at the same price.
- Following these transactions, Khattar directly owns 953,579 shares of common stock and indirectly owns 1,022,450 shares through the KBT Trust.
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions by an executive, with no inherent positive or negative implications.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It's a standard practice for executives to receive and trade company stock as part of their compensation.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.
Key Dates
| Date | Description |
|---|---|
| February 23, 2023 | Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023 and modified on December 12, 2024. |
| February 22, 2024 | Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. |
| December 27, 2024 | Date of stock transactions including acquisition and disposal of shares and performance share units. |
| December 30, 2024 | Date of signature by attorney-in-fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.